The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett syndrome may turn out positive.
Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the company still slipped.
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.
Bio-Rad’s extensive ddPCR assay offerings help researchers leverage the full power of digital PCR.
As novel therapeutics become more complex — and costly — to bring to market, drug developers are looking to unified clinical development platforms to streamline operations.
The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm GLP-1s aren't a "silver bullet" for MASH, one analyst argued.
Създайте своя емисия с новини
Готови ли сте да опитате?
Стартирайте 14-дневен пробен период, не се изисква кредитна карта.